Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 30;42(5):112475.
doi: 10.1016/j.celrep.2023.112475. Epub 2023 May 10.

Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment

Affiliations
Free article

Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment

Hannah Egan et al. Cell Rep. .
Free article

Abstract

Immunosuppressive tumor microenvironments (TMEs) reduce the effectiveness of immune responses in cancer. Mesenchymal stromal cells (MSCs), precursors to cancer-associated fibroblasts (CAFs), promote tumor progression by enhancing immune cell suppression in colorectal cancer (CRC). Hyper-sialylation of glycans promotes immune evasion in cancer through binding of sialic acids to their receptors, Siglecs, expressed on immune cells, which results in inhibition of effector functions. The role of sialylation in shaping MSC/CAF immunosuppression in the TME is not well characterized. In this study, we show that tumor-conditioned stromal cells have increased sialyltransferase expression, α2,3/6-linked sialic acid, and Siglec ligands. Tumor-conditioned stromal cells and CAFs induce exhausted immunomodulatory CD8+ PD1+ and CD8+ Siglec-7+/Siglec-9+ T cell phenotypes. In vivo, targeting stromal cell sialylation reverses stromal cell-mediated immunosuppression, as shown by infiltration of CD25 and granzyme B-expressing CD8+ T cells in the tumor and draining lymph node. Targeting stromal cell sialylation may overcome immunosuppression in the CRC TME.

Keywords: CP: Cancer; CP: Immunology; T cell exhaustion; T cells; cancer-associated fibroblasts; colon cancer; immunotherapy; inflammation; sialylation; siglecs; stromal cells; tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests L.P., W.G., J.C., and P.J. are employees and shareholders of Palleon Pharmaceuticals. M.E.O'D. is a founder of ONK Therapeutics and a member of its Board of Directors and is co-inventor on two related patents (US20210186999A1 and US2017032727899A1). K.L., T.R., and A.E.R. are co-inventors on patent US20210186999A1.

Publication types

MeSH terms

Substances